Asarina Pharma AB (publ) (ASAP.ST)
SEK 0.03
(-31.03%)
SEK 0.03
(-31.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.16 Million SEK | 84.08% |
| 2022 | -13.57 Million SEK | 17.29% |
| 2021 | -16.41 Million SEK | 71.94% |
| 2020 | -58.5 Million SEK | 54.83% |
| 2019 | -129.5 Million SEK | 8.5% |
| 2018 | -141.54 Million SEK | -1588.25% |
| 2017 | -8.38 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | -2.16 Million SEK | 54.3% |
| 2023 Q2 | -4.72 Million SEK | 0.0% |
| 2023 Q1 | -4.72 Million SEK | 65.17% |
| 2023 FY | -2.16 Million SEK | 84.08% |
| 2023 Q4 | -2.16 Million SEK | 0.0% |
| 2022 Q4 | -13.57 Million SEK | 0.0% |
| 2022 FY | -13.57 Million SEK | 17.29% |
| 2022 Q3 | -13.57 Million SEK | -10.36% |
| 2022 Q2 | -12.3 Million SEK | -11.99% |
| 2022 Q1 | -10.98 Million SEK | 33.07% |
| 2021 FY | -16.41 Million SEK | 71.94% |
| 2021 Q4 | -16.41 Million SEK | 8.58% |
| 2021 Q3 | -17.95 Million SEK | 36.44% |
| 2021 Q1 | -41.78 Million SEK | 28.58% |
| 2021 Q2 | -28.25 Million SEK | 32.38% |
| 2020 Q3 | -65.11 Million SEK | 22.33% |
| 2020 Q1 | -109.99 Million SEK | 15.06% |
| 2020 FY | -58.5 Million SEK | 54.83% |
| 2020 Q4 | -58.5 Million SEK | 10.15% |
| 2020 Q2 | -83.82 Million SEK | 23.79% |
| 2019 Q1 | -128.92 Million SEK | 8.92% |
| 2019 Q2 | -109.51 Million SEK | 15.05% |
| 2019 FY | -129.5 Million SEK | 8.5% |
| 2019 Q4 | -129.5 Million SEK | -36.42% |
| 2019 Q3 | -94.92 Million SEK | 13.32% |
| 2018 Q2 | -9.68 Million SEK | -215.47% |
| 2018 FY | -141.54 Million SEK | -1588.25% |
| 2018 Q1 | 8.38 Million SEK | 200.0% |
| 2018 Q4 | -141.54 Million SEK | 0.69% |
| 2018 Q3 | -142.52 Million SEK | -1372.19% |
| 2017 Q4 | -8.38 Million SEK | 0.0% |
| 2017 FY | -8.38 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 140.019% |
| AcouSort AB (publ) | -23.98 Million SEK | 90.991% |
| Active Biotech AB (publ) | -33.2 Million SEK | 93.491% |
| Alzinova AB (publ) | -21.22 Million SEK | 89.819% |
| Amniotics AB (publ) | -5.63 Million SEK | 61.63% |
| BioArctic AB (publ) | -606.58 Million SEK | 99.644% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.815% |
| Cantargia AB (publ) | -139.74 Million SEK | 98.454% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -134.128% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 92.645% |
| Genovis AB (publ.) | -43.94 Million SEK | 95.082% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 97.419% |
| Mendus AB (publ) | -96.29 Million SEK | 97.756% |
| Kancera AB (publ) | -45.69 Million SEK | 95.271% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 97.371% |
| LIDDS AB (publ) | -13.51 Million SEK | 84.007% |
| Lipum AB (publ) | -8.46 Million SEK | 74.471% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 93.231% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 104.06% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 88.662% |
| NextCell Pharma AB | -46.79 Million SEK | 95.382% |
| OncoZenge AB (publ) | -12.62 Million SEK | 82.886% |
| Saniona AB (publ) | 40.44 Million SEK | 105.343% |
| Simris Alg AB (publ) | 85.07 Million SEK | 102.54% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 99.352% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 101.301% |
| Xintela AB (publ) | -7.8 Million SEK | 72.327% |
| Ziccum AB (publ) | -2.13 Million SEK | -1.123% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 98.436% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 98.331% |
| CombiGene AB (publ) | -101.44 Million SEK | 97.87% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 97.367% |
| Intervacc AB (publ) | -88.16 Million SEK | 97.549% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 95.68% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 95.672% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 110.536% |
| Corline Biomedical AB | -17.01 Million SEK | 87.297% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 97.419% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 94.513% |
| Aptahem AB (publ) | 2.9 Million SEK | 174.296% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 99.343% |
| Fluicell AB (publ) | -2.76 Million SEK | 21.788% |
| Biovica International AB (publ) | -58.73 Million SEK | 96.321% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 95.221% |
| Abliva AB (publ) | -57.24 Million SEK | 96.225% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 98.89% |
| 2cureX AB (publ) | -13.4 Million SEK | 83.877% |
| I-Tech AB | -83.26 Million SEK | 97.405% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 101.604% |
| Cyxone AB (publ) | -16.67 Million SEK | 87.037% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 96.133% |
| Biosergen AB | -1.88 Million SEK | -14.764% |
| Nanologica AB (publ) | -9.38 Million SEK | 76.981% |
| SynAct Pharma AB | -61.75 Million SEK | 96.501% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 89.909% |
| BioInvent International AB (publ) | -236.3 Million SEK | 99.086% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 83.665% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 96.771% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 58.289% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 89.607% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 27.288% |